Anti-TIGIT Immunotherapy in Melanoma
August 26, 2025
Checkpoint Inhibitor Therapies and Unmet Needs Checkpoint inhibitor therapies have been a major advance for patients with melanoma. Recent long-term…
The Immunotherapy 360 blog space features articles that encompass prominent issues related to immunotherapy. These are written with the assistance of the staff at AIM at Melanoma, AIM with Immunotherapy and health care practitioners.
If you have an idea for a future article, please reach out to us on our contact page!
A Strategy Aimed at Reducing the Toxicity Associated with TIL Therapy
August 24, 2025
Introduction Tumor-infiltrating lymphocyte (TIL) therapy, such as lifileucel, is approved for use in adults with unresectable, advanced melanoma that has…
Cylembio + Pembrolizumab Shows PFS Benefit in Advanced Melanoma Phase 3 Trial
August 11, 2025
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab)…
Observations Learned from Steroid Use to Manage Immune-Related Adverse Events (irAEs)
August 6, 2025
Helping an individual’s immune system to re-recognize and identify cancer cells has proven to be the most effective drug strategy…
Experiencing the Worst Effects Indicates the Best News for Patients
June 4, 2025
The silver lining for patients experiencing side effects related to immunotherapy and targeted therapy for cancer treatment is that these…
What’s the Issue of Concurrent Statins During Immune Checkpoint Inhibitor Therapy?
May 28, 2025
Introduction Recently, published studies have sparked discussion about combining statins with immune checkpoint inhibitors during cancer treatment. The Journal of…
Ocular Toxicities Associated with Vedotins and Other Antibody-Drug Conjugates are Manageable
April 23, 2025
Introduction In recent years, several antibody-drug conjugates have received approval for the treatment of gynecological cancers, adding powerful tools to…
Potential Biomarker May Indicate T-VEC Efficacy
March 18, 2025
A new study from Harvard University and the Massachusetts General Hospital may have uncovered a biomarker indicating a strong response…
Colitis – A Common but Serious Adverse Event
December 10, 2024
Immune-related adverse events (irAEs) are unintended consequences of immunotherapies used in cancer treatment. Side effects can range from mild to…
Limits of Success Shown for the Combination of Ipilimumab with Nivolumab
December 10, 2024
Immunotherapy is a resounding success for the treatment of many cancer types, including those malignancies which previously had no reliable…